Head and Neck Neoplasms clinical trials
The registry lists 2,717 studies for Head and Neck Neoplasms across more than 10 countries. 598 are recruiting or about to start. 1,512 of them are mainly about Head and Neck Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-19. Counting its 24 narrower conditions too, such as Squamous Cell Carcinoma of Head and Neck: 8,928 studies, 2,538 open.
ClinicalTrials.gov finds 8,825 studies for Head and Neck Neoplasms. How that becomes 2,713 hereChecked on ClinicalTrials.gov . The studies here are updated every night.
This page counts the studies the registry files under Head and Neck Neoplasms, and those it files under no condition that list Head and Neck Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count
- 8,825Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −5,680Filed under a narrower condition, counted on its own pageEsophageal Neoplasms 1,707 · Squamous Cell Carcinoma of Head and Neck 1,316 · Thyroid Neoplasms 644 · Nasopharyngeal Carcinoma 603 · Esophageal Squamous Cell Carcinoma 432 · Mouth Neoplasms 215 · 15 more
- −32List Head and Neck Neoplasms as a condition, but the registry did not file them under itMost often written as “Head and Neck Cancer Squamous Cell Carcinoma” (7), “Squamous Cell Cancer of Head and Neck (SCCHN)” (5), and “Squamous Cell Cancer of Head and Neck” (3). The registry filed 21 of them under no condition at all, and the others under other conditions only, most often Carcinoma, Non-Small-Cell Lung (5) and Melanoma (5).
- −400Match it another way196 name it in the title, 2 in a keyword, and 202 by a synonym or other text the search reads.
- 2,713The count on this page
Get an email when these change. Save the Head and Neck Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Status
Who runs them
M.D. Anderson Cancer Center (74) · Memorial Sloan Kettering Cancer Center (52) · National Cancer Institute (NCI) (35) · University Health Network, Toronto (30) · Vanderbilt-Ingram Cancer Center (30) · Dana-Farber Cancer Institute (27) · University of Chicago (27) · Radiation Therapy Oncology Group (27)
What is being tested here
Drugs under test in Head and Neck Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cisplatin | 11 | 14 | 127 |
| Pembrolizumab | 9 | 6 | 36 |
| Paclitaxel | 8 | 4 | 61 |
| Carboplatin | 7 | 3 | 39 |
| Toripalimab | 5 | 0 | 9 |
| Fluorouracil | 4 | 10 | 44 |
| Nimotuzumab | 4 | 3 | 9 |
| Ficerafusp alfa | 4 | 1 | 4 |
| Docetaxel | 3 | 6 | 68 |
| Panitumumab | 3 | 2 | 14 |
Drug classes tested here Immune checkpoint inhibitors 38 open · Antimitotic agents 12 open · Tyrosine kinase inhibitors (TKIs) 8 open · Antimetabolites 7 open · NSAIDs 4 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy · Phase 3 · University of California, San Francisco
- Dec 2026Head and Neck Cancer Study Project in the Geriatric Population · Phase 3 · Brown University
- Dec 2026A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. · Phase 3 · OncoZenge AB
- Dec 2026Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia · Phase 3 · M.D. Anderson Cancer Center
- Dec 2026Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 3 · West China Hospital
- Mar 2027Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy · Phase 3 · West China Hospital
- May 2027An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors · Phase 3 · Mayo Clinic
- Oct 2027Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers: · Phase 3 · All India Institute of Medical Sciences, Jodhpur
- Nov 2026Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy · Centre Oscar Lambret
- Nov 2026A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment · Harvard Medical School (HMS and HSDM)
Who these studies take
Of the 455 Head and Neck Neoplasms studies recruiting now, 347 (76%) set no upper age limit and 51 (11%) stop at 75 or younger. 22 (5%) take children under 18. 1 (<1%) are for women only and 0 (0%) for men only; 27 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 17 (4%) | 16 (4%) |
| 18 | 429 (94%) | 428 (94%) |
| 30 | 449 (99%) | 448 (98%) |
| 40 | 450 (99%) | 449 (99%) |
| 50 | 450 (99%) | 449 (99%) |
| 65 | 450 (99%) | 449 (99%) |
| 75 | 442 (97%) | 441 (97%) |
| 85 | 375 (82%) | 374 (82%) |
Across all 2,716 studies, recruiting or not: 10% stop at 75 or younger and 2% at 65; 6% take children; <1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Head and Neck Neoplasms studies take
Of 260 phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 51 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 45 mo31–65 · 177 studies | 45 mo29–66 · 86 studies | 42 mo32–63 · 91 studies |
| Phase 1/2 | 54 mo41–79 · 90 studies | 55 mo44–78 · 51 studies | 54 mo31–97 · 39 studies |
| Phase 2 | 51 mo30–76 · 260 studies | 32 mo20–45 · 44 studies | 57 mo37–84 · 216 studies |
| Phase 3 | 61 mo34–100 · 66 studies | — | 76 mo53–108 · 48 studies |
| Interventional, no phase | 33 mo18–70 · 458 studies | — | 34 mo18–71 · 440 studies |
| Observational | 69 mo29–144 · 238 studies | — | 71 mo27–144 · 216 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting11
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Nov 19, 2026NCT07484139
- Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational StudyNov 17, 2026NCT06995417
- PET-CT Imaging With PCD-CTNov 17, 2026NCT07242690
- Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerNov 16, 2026NCT07732634
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyNov 16, 2026NCT07885033
Show 6 moreShow fewer
- A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)Nov 6, 2026NCT07418034
- Feasibility of Cough Skill Training in Individuals With Head and Neck CancerOct 30, 2026NCT07756684
- Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in RadiotherapyOct 29, 2026NCT07185958
- Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck CancerOct 29, 2026NCT07704372
- Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Oct 27, 2026NCT06295731
- Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck CancerOct 20, 2026NCT06929468
Results posted1
Stopped1
Newly registered27
- Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III TrialNov 19, 2026NCT07948317
- FLASH Biomarker StudyNov 17, 2026NCT07942077
- Role of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological PathologyNov 17, 2026NCT07942090
- Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor BoardsNov 16, 2026NCT07939139
- Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck CancerNov 12, 2026NCT07932067
Show 22 moreShow fewer
- EVEREST-HN-3: Linkage of National Data Sets for Suspected Head-and-neck Cancer ReferralsNov 12, 2026NCT07933588
- LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell CarcinomaNov 12, 2026NCT07934316
- Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter StudyNov 10, 2026NCT07927764
- MyPatientPal+: A Smartphone App and a Provider Dashboard to Manage Patient Care While on TreatmentNov 10, 2026NCT07928154
- Unplanned Hospitalization and Emergency Department Use in Patients With Head and Neck Cancer Receiving RadiotherapyNov 10, 2026NCT07929194
- Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer SurgeryNov 6, 2026NCT07922759
- Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm TrialNov 6, 2026NCT07922967
- Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot StudyNov 5, 2026NCT07919444
- Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot StudyNov 5, 2026NCT07919457
- Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal CarcinomaNov 5, 2026NCT07920250
- Head and Neck Cancer StrategiesNov 2, 2026NCT07909603
- Airway Ultrasound in Oncologic Maxillofacial PatientsNov 2, 2026NCT07910149
- Intraoperative Visualization of Large Head and Neck Tumors to Optimize Radiation Therapy Planning Using Liquid Soft-tissue Markers Such as BioXmark® (During Definitive Treatment or in the Postoperative Setting)Nov 2, 2026NCT07910799
- Gut-Liver-Muscle Axis in Cancer CachexiaNov 2, 2026NCT07911150
- Determinants of Radiation Dermatitis in Head and Neck Cancer Patients Receiving Preventive PhotobiomodulationOct 28, 2026NCT07899866
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaOct 28, 2026NCT07901959
- Effect of Abdominal Massage on Gastrointestinal Symptoms After Head and Neck Cancer SurgeryOct 22, 2026NCT07889011
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyOct 21, 2026NCT07885033
- Radiotherapy In a Sitting Position for Enhanced ReproducibilityOct 21, 2026NCT07887048
- Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCCOct 20, 2026NCT07882888
- SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck CancerOct 20, 2026NCT07883005
- Surgical Margin Assessment Using Intra-operative High-resolution PET/CT in Patients With Cancers Referred to Surgical Resection, an Exploratory Pilot StudyOct 20, 2026NCT07884487
Studies
Recruiting first, then most recently updated. Showing 50 of 2,717. Browse all 2,717 → or search them.
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCRecruitingNCT06788990Phase 2/328 countries
- Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy ParticipantsRecruitingNCT008986381 country
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/21 country
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)RecruitingNCT07484139Phase 21 country
- Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III TrialNot yet recruitingNCT07948317Phase 3
- Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site SequelaeRecruitingNCT05757817Not applicable1 country
- Deciphering Mechanisms Underlying Cancer ImmunogenicityRecruitingNCT03958240Not applicable1 country
- Analysis of Breath Volatile Organic Compounds Using Mass SpectrometryNot yet recruitingNCT077326861 country
- Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 21 country
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsRecruitingNCT07020117Phase 11 country
- Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational StudyRecruitingNCT069954171 country
- Role of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological PathologyEnrolling by invitationNCT07942090Not applicable1 country
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 216 countries
- PET-CT Imaging With PCD-CTRecruitingNCT07242690Not applicable1 country
- FLASH Biomarker StudyNot yet recruitingNCT079420771 country
- A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCRecruitingNCT07462377Phase 13 countries
- Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor BoardsRecruitingNCT079391391 country
- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METRecruitingNCT07873450Phase 1/23 countries
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) ProductsEnrolling by invitationNCT068854241 country
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyRecruitingNCT07885033Not applicable1 country
- Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerRecruitingNCT07732634Phase 21 country
- Stereotactic Boost and Short-course Radiation Therapy for Oropharynx CancerRecruitingNCT04178174Phase 32 countries
- Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With PathologyRecruitingNCT025071411 country
- Effect of Prehabilitation on Head and Neck Cancer PatientsRecruitingNCT06593639Not applicable1 country
- Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaRecruitingNCT07741643Phase 11 country
- LIMA1 Immunohistochemistry and Depth of Invasion as Prognostic Biomarkers in Oral Squamous Cell CarcinomaEnrolling by invitationNCT079343161 country
- Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck CancerNot yet recruitingNCT07932067Phase 21 country
- Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07741565Early Phase 11 country
- Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral CancerRecruitingNCT06627270Phase 21 country
- Unplanned Hospitalization and Emergency Department Use in Patients With Head and Neck Cancer Receiving RadiotherapyNot yet recruitingNCT079291941 country
- Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]RecruitingNCT06125743Not applicable1 country
- Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy PatientsRecruitingNCT07631650Phase 21 country
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1RecruitingNCT07292168Phase 1/21 country
- A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal CancerRecruitingNCT06319963Phase 1/21 country
- MyPatientPal+: A Smartphone App and a Provider Dashboard to Manage Patient Care While on TreatmentNot yet recruitingNCT07928154Not applicable1 country
- Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter StudyNot yet recruitingNCT07927764
- Biospecimen Procurement for Head and Neck DisordersRecruitingNCT034290361 country
- A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)RecruitingNCT07418034Phase 21 country
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/24 countries
- Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer SurgeryRecruitingNCT07922759Phase 41 country
- Impact of Chronic MICROplastic Exposure on RADiotherapy of Head and Neck Cancer Patients: Clinical and Translational Oncology Study:Not yet recruitingNCT07690631
- Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm TrialRecruitingNCT079229671 country
- A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation TherapyRecruitingNCT052070981 country
- Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot StudyRecruitingNCT07919444Phase 21 country
- Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot StudyRecruitingNCT07919457Phase 21 country
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 16 countries
- Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCCRecruitingNCT06096038Phase 11 country
- Gut-Liver-Muscle Axis in Cancer CachexiaNot yet recruitingNCT07911150Not applicable1 country
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/22 countries
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseRecruitingNCT053668811 country